Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18
- M. Kim
- , J. L. Lee
- , S. J. Shin
- , W. K. Bae
- , H. J. Lee
- , J. H. Byun
- , Y. J. Choi
- , J. Youk
- , C. Y. Ock
- , S. Kim
- , H. Song
- , K. H. Park
- , B. Keam*
*Corresponding author for this work
Research output: Contribution to journal › Article › peer-review
11
Link opens in a new tab
Citations
(Scopus)